Date: 2015-10-14
Type of information: Nomination
Compound:
Company: Nabriva Therapeutics (Austria)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 14, 2015, Nabriva Therapeutics, a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, announced the appointment of Will Sargent as Vice President, Commercial Strategy and Investor Relations, a newly created position. Mr. Sargent will be based at the company\'s U.S. headquarters in King of Prussia, PA. Will Sargent will lead development of commercial strategy for the launch of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and corporate communications/investor relations; he will also support the lefamulin development program for additional indications. Mr. Sargent joins Nabriva with two decades of experience in the biopharmaceutical industry, including multiple product and line extension launches. Most recently, he served as Vice President, Orthopedic Business Unit at Auxilium Pharmaceuticals where he led the company\'s marketing and sales team advancing Xiaflex® for the treatment of Dupuytren\'s contracture and development of additional pipeline indications. Prior to his commercial responsibilities, Mr. Sargent built the corporate communications and investor relations capacity at Auxilium, which became a subsidiary of ENDO International in 2015. Before Auxilium, Mr. Sargent was a biotechnology equities analyst at Bank of America and held multiple commercial roles at Amgen and Immunex. At Amgen, he led medical marketing activities for the launch of Enbrel in psoriasis. Mr. Sargent received his Bachelor of Arts in Biology from Johns Hopkins University and an MBA from the University of Washington.
Financial terms:
Latest news:
